Benefits
UTI Prevention via E. coli Anti-Adhesion
D-mannose binds to type-1 fimbriated E. coli (causes ~80% of UTIs) preventing adhesion to bladder wall — bacteria flushed out via urination.
Recurrent UTI Management
D-mannose has clinical evidence for reducing UTI recurrence in women with history of recurrent UTIs.
Comparable to Antibiotic Prophylaxis
Some trials show D-mannose comparable efficacy to antibiotic prophylaxis for UTI prevention with fewer side effects and no antibiotic resistance concerns.
Highest-Purity Form
BLS positioning emphasizes high-purity D-mannose — quality differentiation in supplement market.
Urinary System Mechanism
Concentrated in urinary tract via renal excretion; targets bladder where UTIs occur.
Versatile Format Compatibility
Featured in fruit gummies and other formats — consumer-friendly delivery.
Mechanism of action
E. coli Type-1 Fimbriae Binding
D-mannose specifically binds to FimH adhesin on type-1 fimbriae of E. coli — the lectin used by E. coli to adhere to urothelial cells. Mannose-bound E. coli cannot adhere; flushed via urination.
Renal Excretion Concentration
D-mannose is poorly metabolized; ~90% excreted unchanged via kidneys; concentrates in urinary tract — targets UTI pathogens at site of infection.
No Bacterial Resistance Mechanism
Unlike antibiotics, D-mannose works via physical anti-adhesion — bacteria cannot develop resistance to physical interaction.
Selective for E. coli
Targets specific E. coli adhesion mechanism without affecting other bacteria — preserves microbiome.
Clinical trials
Multiple D-mannose RCTs in women with recurrent UTIs.
Women with recurrent UTIs.
Significant reduction in UTI recurrence vs placebo; comparable to antibiotic prophylaxis in some trials.
About this ingredient
MANNOHEALTH is a HIGH-PURITY D-MANNOSE ingredient from BIOENERGY LIFE SCIENCE (BLS, Minneapolis). D-MANNOSE BACKGROUND: simple sugar (monosaccharide) isomer of glucose; naturally occurs in cranberries, apples, peaches; minimally metabolized in body; primarily excreted unchanged in urine; concentrated mechanism of action in urinary tract.
KEY DISTINCTIONS: (1) HIGH-PURITY positioning; (2) BLS quality and supply; (3) Gummy and other format compatibility; (4) Distinct from BLS's NAD+/ATP-focused RiaGev portfolio; (5) Targeted urinary health applications.
EVIDENCE-BASED USES: (1) UTI prevention; (2) Recurrent UTI management; (3) Urinary tract health; (4) E. coli-mediated infection prevention.
CRITICAL CAUTIONS: (1) ACTIVE UTI vs PREVENTION — D-mannose useful for prevention and adjunct; established UTIs typically require antibiotics; symptoms (burning, urgency, fever) warrant medical evaluation; (2) E. COLI SPECIFICITY — D-mannose targets E. coli (most common UTI pathogen ~80%); ineffective against non-E. coli UTIs (Klebsiella, Proteus, etc); (3) DOSE — 2 g/day for prevention; higher for active UTI adjunct under medical supervision; (4) DIABETES — D-mannose minimally metabolized but verify glucose effects; (5) PREGNANCY — generally considered safe; some use for UTI prevention during pregnancy; consult; (6) MANNOHEALTH vs PACRAN (Naturex/Givaudan) — different mechanisms; both UTI prevention; D-mannose physical anti-adhesion; cranberry PAC anti-adhesion; complementary; can be combined; (7) MANNOHEALTH vs CRANBERRY GENERICS — D-mannose more concentrated mechanism; cranberry whole-fruit broader effects; both have applications; (8) MANNOHEALTH vs ANTIBIOTIC PROPHYLAXIS — D-mannose comparable efficacy in some trials with fewer side effects; no resistance development; antibiotic-sparing strategy; (9) FOR RECURRENT UTI MANAGEMENT — D-mannose primary natural intervention; alongside hydration, hygiene, possibly cranberry; (10) BRAND VERIFICATION — MannoHealth is Bioenergy Life Science trademark.